Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 7/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22033078 | 0.90 | MEN1 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL17184276 | 0.87 | MAPT (0.39) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL22033300 | 0.86 | POLB (0.48) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL17195407 | 0.85 | TP53 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL22032937 | 0.85 | TP53 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL15668196 | 0.84 | POLB (0.53) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL14686484 | 0.81 | TP53 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL22033068 | 0.81 | PIK3C3 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL15668570 | 0.80 | POLB (0.59) | SLC6A2SLC6A4SLC6A3KCNH2TP53 | |
| SCHEMBL25423218 | 0.79 | POLB (0.54) | TP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2914253-B1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANTBIOSCIENCE INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | SMO, SHH, SOS1 | SLC6A2 4680/4885SLC6A4 4033/4885SLC6A3 4002/4885 |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | SLC6A2 4680/4885SLC6A4 4033/4885SLC6A3 4002/4885 |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | SLC6A2 4680/4885SLC6A4 4033/4885SLC6A3 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.